The APOL2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the APOL2 gene in the human A-549 lung adenocarcinoma cell line. This product provides a heterogeneous pool of gene-edited cells, enabling loss-of-function studies of the apolipoprotein L2 (APOL2) in a physiologically relevant epithelial model. The polyclonal population contains a diverse array of gene-edited alleles, ensuring that observed phenotypes are robust and not due to clonal artifacts. This format is particularly useful for functional genomics screens and for studies where biological heterogeneity is critical, allowing researchers to interrogate APOL2-dependent phenotypes across a broad genetic background.
The A-549 cell line, derived from the lung adenocarcinoma of a 58-year-old Caucasian male, is widely used as a model of alveolar type II pneumocytes. These adherent epithelial cells retain key characteristics of lung adenocarcinoma, including the ability to form monolayers, express surfactant proteins, and engage in lipid metabolism and inflammatory signaling pathways. A-549 cells are extensively employed in lung cancer research for studying oncogenic signaling, metastatic potential, and therapeutic responses. Their capacity for lipid accumulation and responsiveness to inflammatory cytokines make them a relevant model for investigating metabolic reprogramming and immune interactions in the tumor microenvironment.
APOL2 functions as a lipid-binding apolipoprotein involved in lipid transport, innate immunity modulation, and apoptosis regulation. It is transcriptionally upregulated by interferon-gamma (IFNG) and interferon-alpha (IFNA) through the JAK-STAT pathway; activated STAT1 translocates to the nucleus and cooperates with IRF1 to induce APOL2 expression. The APOL2 protein then associates with high-density lipoprotein (HDL) particles and interacts with APOA1 to facilitate lipid complex formation and intracellular lipid trafficking. Downstream, APOL2 modulates lipid droplet accumulation and influences the balance of pro- and anti-apoptotic factors, including BCL2 and BAX. This regulation impacts downstream caspase activation, notably CASP3, thereby connecting immune signals with cell death pathways. Thus, APOL2 serves as a critical node integrating extracellular immune cues with intracellular lipid metabolism and apoptosis.
In the A-549 lung adenocarcinoma context, APOL2 knockout is expected to perturb lipid metabolism, alter apoptotic thresholds, and modify interferon-mediated immune responses. For instance, loss of APOL2 may enhance or suppress lipid droplet accumulation, potentially affecting energy storage and membrane biosynthesis. In apoptosis assays, APOL2 knockout may sensitize cells to intrinsic or extrinsic death stimuli, providing insights into chemoresistance mechanisms. Moreover, given the link between interferon signaling and tumor immunity, APOL2-deficient A-549 cells can be used to explore how lipid metabolism influences antigen presentation or cytokine production, making this model valuable for studying the interplay between lipid dysregulation and cancer cell survival.
Researchers can employ these polyclonal knockout cells in a broad array of applications, including cancer biology, lipid metabolism, apoptosis, and drug resistance research, as well as lung adenocarcinoma modeling. Typical assays compatible with this model include western blotting, RT-qPCR, immunofluorescence, flow cytometry, apoptosis assays, lipid droplet staining, cell viability assays, and drug sensitivity screening. The cells are also suitable for high-content screening of small-molecule inhibitors, genetic complementation studies, and co-culture experiments with immune cells to investigate tumor-immune interactions. The polyclonal nature reduces clonal variation and enhances reproducibility. For additional technical specifications or ordering information, please contact Ascent Research.
